Bharat Biotech on Tuesday announced expansion of its manufacturing capacity to produce as many as 700 million doses of Covaxin annually.
Covaxin has received Emergency Use Authorisations (EUA)s in several countries with another 60 in process.
EUAs have now been obtained from Mexico, Philippines, Iran, Paraguay, Guatemala, Nicaragua, Guyana, Venezuela, Botswana and Zimbabwe, among other countries.
